- Home
- All Stock List
- NSE
- Strides Pharma Science Ltd Share Price
657.75
-4.40 (-0.66%)
-
Outperforms Index
71.51%
Return (1Y)
Beaten Nifty 50 by 60.49%
-
More Volatile
3.12%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.14%
-
Consistent Performer
8/12
Months
beaten Nifty 50
-
AxisDirect View
No View
761
301
News & Announcements
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 15 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
-
-
Strides Pharma Science announces acquisition of Singapore-based Amexel
15 - Mar - 2025 12:00 | 61 days ago
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform.
SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
Amexel, as WOS of SPG, shall focus on: ?h
- in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides?? manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. ?h
- identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. ?h
- building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.
Powered by Capital Market - Live News
-
-
Strides Pharma Science announces acquisition of Singapore-based Amexel
15 - Mar - 2025 12:00 | 61 days ago
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform.
SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
Amexel, as WOS of SPG, shall focus on: ?h
- in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides?? manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. ?h
- identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. ?h
- building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.
Powered by Capital Market - Live News
-
Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025.
Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025.
Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.
Powered by Capital Market - Live News
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 15 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
-
-
Strides Pharma Science announces acquisition of Singapore-based Amexel
15 - Mar - 2025 12:00 | 61 days ago
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform.
SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
Amexel, as WOS of SPG, shall focus on: ?h
- in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides?? manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. ?h
- identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. ?h
- building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.
Powered by Capital Market - Live News
-
Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025.
Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025.
Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.
Powered by Capital Market - Live News
-
Strides Pharma?s US arm acquires four drugs to bolster portfolio
30 - Apr - 2025 12:00 | 15 days ago
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.
The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).
Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products
The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.
The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
Powered by Capital Market - Live News
-
-
Strides Pharma Science announces acquisition of Singapore-based Amexel
15 - Mar - 2025 12:00 | 61 days ago
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform.
SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
Amexel, as WOS of SPG, shall focus on: ?h
- in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides?? manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. ?h
- identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. ?h
- building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.
Powered by Capital Market - Live News
-
-
Strides Pharma Science announces acquisition of Singapore-based Amexel
15 - Mar - 2025 12:00 | 61 days ago
Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform.
SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
Amexel, as WOS of SPG, shall focus on: ?h
- in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides?? manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. ?h
- identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. ?h
- building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.
Powered by Capital Market - Live News
-
Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025.
Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025.
Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.
Powered by Capital Market - Live News
Stock Trivia
MF shareholding in Strides Shasun Ltd has decreased by -18.16% since past 3 Months
MF shareholding in Strides Shasun Ltd has decreased by -15.88% since past 1 Year
MF shareholding in Strides Shasun Ltd has decreased by -18.16% since past 3 Months
Promoter shareholding in Strides Shasun Ltd has increased by 5.49% since past 3 Months
FII shareholding in Strides Shasun Ltd has increased by 15.28% since past 1 Year
MF shareholding in Strides Shasun Ltd has decreased by -15.88% since past 1 Year
MF shareholding in Strides Shasun Ltd has decreased by -18.16% since past 3 Months
MF shareholding in Strides Shasun Ltd has decreased by -15.88% since past 1 Year
